71 completed. 71 Phase 1, 22 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 71 | Completed 71 |
| Phase 2 | 22 | Completed 22 |
Follow Acute Lymphoblastic Leukemia: new trials by email Literature Review of Acute Lymphoblastic Leukemia trials Research Report on Acute Lymphoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia 14C-bleximenib, bleximenib - Acute Lymphoblastic Leukemia, Acute Leukemias | Phase 1 | Completed | Janssen Research & Development, LLC | 6 | 2025-11-18 | 2026-09-25 |
| Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies Fludarabine, Cyclophosphamide, PRGN-3007 - Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 3 | 2023-01-25 | 2026-02-06 |
| Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia CAR-NK-CD19 Cells - Acute Lymphoblastic Leukemia | Phase 1 | Completed | Shanghai Simnova Biotechnology Co.,Ltd. | 2 | 2022-07-21 | 2022-11-28 |
| A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia Revumenib, Chemotherapy Regimen 1, Chemotherapy Regimen 2 - Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia | Phase 1 | Completed | Syndax Pharmaceuticals | 30 | 2022-03-09 | 2024-08-13 |
| Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings vaccine COMIRNATY® (BNT162b2) - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 76 | 2021-09-29 | 2024-06-26 |
| Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL Blinatumomab, AMG 404, Dexamethasone Premedication - Acute Lymphoblastic Leukemia | Phase 1 | Completed | Amgen | 17 | 2020-10-02 | 2024-04-08 |
| Haplo Peripheral Blood Sct In GVHD Prevention FLUDARABINE, CYCLOPHOSPHAMIDE, TBI - GVHD, AML | Phase 1 | Completed | Zachariah Michael DeFilipp | 25 | 2020-08-14 | 2025-07-20 |
| TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia TC-110 T Cells, Fludarabine, Cyclophosphamide - Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Completed | TCR2 Therapeutics | 6 | 2020-03-27 | 2023-03-16 |
| Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents pCAR-19B cells - Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL | Phase 1 | Completed | Chongqing Precision Biotech Co., Ltd | 9 | 2019-11-05 | 2022-03-18 |
| Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia Intravenous fluids - Lymphoma, Acute Lymphoblastic Leukemia | Phase 1 | Completed | Virginia Commonwealth University | 10 | 2019-10-02 | 2024-02-13 |
| Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL anti-CD19/CD22 CAR-T cells, Fludarabine, Cyclophosphamide - MRD-positive, Acute Lymphoblastic Leukemia | Phase 1 | Completed | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 19 | 2019-08-11 | 2023-12-08 |
| A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 CPX-351 - Hematologic Malignancy, Acute Myeloid Leukemia | Phase 1 | Completed | Jazz Pharmaceuticals | 21 | 2018-11-20 | 2021-07-22 |
| Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 Natural Killer (NK) Cells, ALT803 - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Completed | Brenda Cooper, MD | 14 | 2018-05-22 | 2023-02-21 |
| CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies CD19/CD22 CAR T-Cells, Fludarabine, Cyclophosphamide - Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, B Cell | Phase 1 | Completed | National Cancer Institute (NCI) | 54 | 2018-03-26 | 2025-06-04 |
| Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Cyclophosphamide, Filgrastim, Fludarabine Phosphate - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 11 | 2017-01-18 | 2023-02-16 |
| Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies ProTmune, Control Arm - Hematologic Malignancies, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Fate Therapeutics | 96 | 2016-12-20 | 2023-02-08 |
| Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine Bendamustine, Cyclophosphamide - Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia | Phase 1 | Completed | University of Arizona | 50 | 2016-11-29 | 2025-11-10 |
| Thiopurine EnhAnced Maintenance Therapy Thioguanine (oral) - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | Phase 1 / Phase 2 | Completed | Kjeld Schmiegelow | 30 | 2016-10-01 | 2020-04-15 |
| Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia Yttrium-90 labelled monoclonal antibody against CD66 - Acute Myeloblastic Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Completed | Great Ormond Street Hospital for Children NHS Foundation Trust | 9 | 2016-05-01 | 2021-06-25 |
| Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Cyclophosphamide, Cytarabine, Dasatinib - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Completed | OHSU Knight Cancer Institute | 7 | 2016-01-13 | 2020-05-26 |
Showing 20 of 71. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (71) · Leukemia, Myeloid, Acute (38) · Myelodysplastic Syndromes (19) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (16) · Lymphoma, Non-Hodgkin (15) · Leukemia (13) · Burkitt Lymphoma (9) · Leukemia, Lymphocytic, Chronic, B-Cell (9) · Hodgkin Disease (8) · Multiple Myeloma (7) · Lymphoma, Large B-Cell, Diffuse (6) · Lymphoma (5) · Recurrence (5) · Hematologic Neoplasms (4) · Leukemia, Myelomonocytic, Chronic (4)
Hematologic Diseases (71) · Hemic and Lymphatic Diseases (71) · Immune System Diseases (71) · Immunoproliferative Disorders (70) · Leukemia, Lymphoid (70) · Lymphatic Diseases (70) · Lymphoproliferative Disorders (70) · Neoplasms by Histologic Type (70) · Neoplasms (67) · Leukemia (58) · Leukemia, Myeloid (42) · Pathologic Processes (31) · Pathological Conditions, Signs and Symptoms (31) · Disease Attributes (29) · Bone Marrow Diseases (28)
Cyclophosphamide (18) · Cytarabine (8) · Vincristine (8) · Clofarabine (7) · fludarabine phosphate (7) · Dexamethasone (6) · Doxorubicin (6) · fludarabine (6) · Methotrexate (5) · pegaspargase (5) · Calcium Dobesilate (4) · Mercaptopurine (4) · Etoposide (3) · Granulocyte Colony-Stimulating Factor (3) · Mycophenolic Acid (3)
St. Jude Children's Research Hospital (4) · M.D. Anderson Cancer Center (3) · National Cancer Institute (NCI) (3) · Dana-Farber Cancer Institute (2) · Genzyme, a Sanofi Company (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Millennium Pharmaceuticals, Inc. (2) · New York Medical College (2) · Novartis Pharmaceuticals (2) · AbbVie (prior sponsor, Abbott) (1) · Abramson Cancer Center at Penn Medicine (1) · Acrotech Biopharma Inc. (1) · Amgen (1) · Amgen Research (Munich) GmbH (1) · Asan Medical Center (1)
United States (50) · Canada (6) · France (5) · Italy (5) · Germany (4) · Netherlands (4) · United Kingdom (4) · Australia (3) · China (3) · Japan (3) · Austria (2) · Spain (2) · Brazil (1) · Denmark (1) · Israel (1)
Lewis Silverman, MD (2) · Nirali N Shah, M.D. (2) · Amy DeZern, MD, MHS (1) · Arend von Stackelberg, MD (1) · Ashok Srinivasan, MD (1) · Brenda Sandmaier (1) · Cady P Noda, PharmD (1) · Damon Reed, M.D. (1) · David A Rizzieri, MD (1) · David Wald, MD, PhD (1) · Deborah Thomas, MD (1) · Emmanuel Katsanis, MD (1)
PMID 34687939, PMID 37486616, PMID 18824593, PMID 19965642, PMID 20582937, PMID 21967976, PMID 22653976, PMID 24869942, PMID 25082342, PMID 25612623, PMID 25733005, PMID 25933833, PMID 26341814, PMID 27063977, PMID 27063978, PMID 27198129, PMID 27998223, PMID 28588018, PMID 28983018, PMID 29724899, PMID 29908231, PMID 31355467, PMID 31770437, PMID 32286905, PMID 32582591, PMID 32993794, PMID 33656536, PMID 34309174, PMID 34592755, PMID 34889384, PMID 34932836, PMID 35460929, PMID 35605184, PMID 35847727, PMID 37295816, PMID 37738655, PMID 38376944, PMID 38473278, PMID 39868759, PMID 40270968, PMID 40641817, PMID 41114449, PMID 41411486, PMID 42248607
N01CM00071 (1), N01CM62201 (1), N01CM62209 (1), P01CA078902 (1), P30CA006973 (1), P30CA015704 (1), P30CA069533 (1), U01CA062487 (1), U01CA062502 (1), U01CA070095 (1), U10CA098413 (1), U10CA098543 (1), U10CA180886 (1), U10CA180899 (1), UM1CA186691 (1)